Logo image of TVTX

TRAVERE THERAPEUTICS INC (TVTX) Stock Fundamental Analysis

NASDAQ:TVTX - Nasdaq - US89422G1076 - Common Stock - Currency: USD

16.11  -0.49 (-2.95%)

Fundamental Rating

3

Taking everything into account, TVTX scores 3 out of 10 in our fundamental rating. TVTX was compared to 561 industry peers in the Biotechnology industry. TVTX may be in some trouble as it scores bad on both profitability and health. TVTX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TVTX has reported negative net income.
In the past year TVTX has reported a negative cash flow from operations.
In the past 5 years TVTX always reported negative net income.
In the past 5 years TVTX always reported negative operating cash flow.
TVTX Yearly Net Income VS EBIT VS OCF VS FCFTVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

TVTX has a Return On Assets of -41.31%. This is comparable to the rest of the industry: TVTX outperforms 53.48% of its industry peers.
TVTX has a worse Return On Equity (-690.70%) than 82.00% of its industry peers.
Industry RankSector Rank
ROA -41.31%
ROE -690.7%
ROIC N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
TVTX Yearly ROA, ROE, ROICTVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 96.01%, TVTX belongs to the top of the industry, outperforming 94.83% of the companies in the same industry.
In the last couple of years the Gross Margin of TVTX has remained more or less at the same level.
TVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
TVTX Yearly Profit, Operating, Gross MarginsTVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TVTX has been increased compared to 1 year ago.
Compared to 5 years ago, TVTX has more shares outstanding
The debt/assets ratio for TVTX is higher compared to a year ago.
TVTX Yearly Shares OutstandingTVTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TVTX Yearly Total Debt VS Total AssetsTVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -2.52, we must say that TVTX is in the distress zone and has some risk of bankruptcy.
TVTX has a Altman-Z score (-2.52) which is in line with its industry peers.
TVTX has a Debt/Equity ratio of 9.46. This is a high value indicating a heavy dependency on external financing.
TVTX has a Debt to Equity ratio of 9.46. This is amonst the worse of the industry: TVTX underperforms 85.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 9.46
Debt/FCF N/A
Altman-Z -2.52
ROIC/WACCN/A
WACC9.32%
TVTX Yearly LT Debt VS Equity VS FCFTVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

TVTX has a Current Ratio of 2.05. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
TVTX has a Current ratio of 2.05. This is in the lower half of the industry: TVTX underperforms 74.69% of its industry peers.
TVTX has a Quick Ratio of 2.03. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TVTX (2.03) is worse than 73.08% of its industry peers.
Industry RankSector Rank
Current Ratio 2.05
Quick Ratio 2.03
TVTX Yearly Current Assets VS Current LiabilitesTVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

TVTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.79%, which is quite impressive.
The Revenue has grown by 111.02% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 5.87% on average over the past years.
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.3%
Revenue 1Y (TTM)111.02%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%97.54%

3.2 Future

TVTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.87% yearly.
Based on estimates for the next years, TVTX will show a very strong growth in Revenue. The Revenue will grow by 40.36% on average per year.
EPS Next Y72.14%
EPS Next 2Y50.61%
EPS Next 3Y33.94%
EPS Next 5Y26.87%
Revenue Next Year71.91%
Revenue Next 2Y59.99%
Revenue Next 3Y46.34%
Revenue Next 5Y40.36%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TVTX Yearly Revenue VS EstimatesTVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
TVTX Yearly EPS VS EstimatesTVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 8

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
TVTX is valuated correctly with a Price/Forward Earnings ratio of 14.65.
94.12% of the companies in the same industry are more expensive than TVTX, based on the Price/Forward Earnings ratio.
TVTX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.94.
Industry RankSector Rank
PE N/A
Fwd PE 14.65
TVTX Price Earnings VS Forward Price EarningsTVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVTX Per share dataTVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TVTX's earnings are expected to grow with 33.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.61%
EPS Next 3Y33.94%

More info and screens

0

5. Dividend

5.1 Amount

TVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRAVERE THERAPEUTICS INC

NASDAQ:TVTX (5/22/2025, 10:49:31 AM)

16.11

-0.49 (-2.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners112.17%
Inst Owner Change5.05%
Ins Owners0.91%
Ins Owner Change13.1%
Market Cap1.43B
Analysts84.55
Price Target34.34 (113.16%)
Short Float %12.19%
Short Ratio6.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.01%
Min EPS beat(2)-27.29%
Max EPS beat(2)15.26%
EPS beat(4)1
Avg EPS beat(4)-4.16%
Min EPS beat(4)-27.29%
Max EPS beat(4)15.26%
EPS beat(8)3
Avg EPS beat(8)-96.36%
EPS beat(12)4
Avg EPS beat(12)-67.7%
EPS beat(16)5
Avg EPS beat(16)-54.4%
Revenue beat(2)1
Avg Revenue beat(2)1.63%
Min Revenue beat(2)-0.02%
Max Revenue beat(2)3.29%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)5.75%
Revenue beat(8)5
Avg Revenue beat(8)-5.96%
Revenue beat(12)7
Avg Revenue beat(12)-14.72%
Revenue beat(16)9
Avg Revenue beat(16)-10.64%
PT rev (1m)0%
PT rev (3m)19.39%
EPS NQ rev (1m)21.17%
EPS NQ rev (3m)13.23%
EPS NY rev (1m)22.22%
EPS NY rev (3m)13.18%
Revenue NQ rev (1m)16.55%
Revenue NQ rev (3m)24.22%
Revenue NY rev (1m)3.63%
Revenue NY rev (3m)10.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.65
P/S 5.23
P/FCF N/A
P/OCF N/A
P/B 43.57
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)1.1
Fwd EY6.83%
FCF(TTM)-3.01
FCFYN/A
OCF(TTM)-1.81
OCFYN/A
SpS3.08
BVpS0.37
TBVpS-0.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.31%
ROE -690.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.01%
FCFM N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 9.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 229.21%
Cap/Sales 38.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.05
Quick Ratio 2.03
Altman-Z -2.52
F-Score4
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.3%
EPS Next Y72.14%
EPS Next 2Y50.61%
EPS Next 3Y33.94%
EPS Next 5Y26.87%
Revenue 1Y (TTM)111.02%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%97.54%
Revenue Next Year71.91%
Revenue Next 2Y59.99%
Revenue Next 3Y46.34%
Revenue Next 5Y40.36%
EBIT growth 1Y38.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.88%
EBIT Next 3Y51.31%
EBIT Next 5Y33.05%
FCF growth 1Y-1.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.25%
OCF growth 3YN/A
OCF growth 5YN/A